Alnylam Pharmaceuticals Inc. Q1 Loss Decreases, beats estimates

Alnylam Pharmaceuticals Inc. (ALNY) revealed Loss for its first quarter that increased from last year and missed the Street estimates.

The company's earnings totaled -$240.34 million, or -$2.00 per share. This compares with -$200.29 million, or -$1.71 per share, in last year's first quarter.

Excluding items, Alnylam Pharmaceuticals Inc. reported adjusted earnings of -$179.89 million or -$1.49 per share for the period.

Analysts on average had expected the company to earn -$1.84 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.

The company's revenue for the quarter rose 37.6% to $186.87 million from $135.77 million last year.

Alnylam Pharmaceuticals Inc. earnings at a glance (GAAP) :

-Earnings (Q1): -$240.34 Mln. vs. -$200.29 Mln. last year.
-EPS (Q1): -$2.00 vs. -$1.71 last year.
-Analyst Estimate: -$1.84
-Revenue (Q1): $186.87 Mln vs. $135.77 Mln last year.

For comments and feedback contact: editorial@rttnews.com

Follow RTT